Impact of the gut microbiome on nicotine's motivational effects and glial cells in the ventral tegmental area in male mice.


Journal

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
ISSN: 1740-634X
Titre abrégé: Neuropsychopharmacology
Pays: England
ID NLM: 8904907

Informations de publication

Date de publication:
05 2023
Historique:
received: 26 09 2022
accepted: 25 02 2023
revised: 22 02 2023
pmc-release: 01 05 2024
medline: 5 5 2023
pubmed: 19 3 2023
entrez: 18 3 2023
Statut: ppublish

Résumé

A link between gut dysbiosis and the pathogenesis of brain disorders has been identified. A role for gut bacteria in drug reward and addiction has been suggested but very few studies have investigated their impact on brain and behavioral responses to addictive drugs so far. In particular, their influence on nicotine's addiction-like processes remains unknown. In addition, evidence shows that glial cells shape the neuronal activity of the mesolimbic system but their regulation, within this system, by the gut microbiome is not established. We demonstrate that a lack of gut microbiota in male mice potentiates the nicotine-induced activation of sub-regions of the mesolimbic system. We further show that gut microbiota depletion enhances the response to nicotine of dopaminergic neurons of the posterior ventral tegmental area (pVTA), and alters nicotine's rewarding and aversive effects in an intra-VTA self-administration procedure. These effects were not associated with gross behavioral alterations and the nicotine withdrawal syndrome was not impacted. We further show that depletion of the gut microbiome modulates the glial cells of the mesolimbic system. Notably, it increases the number of astrocytes selectively in the pVTA, and the expression of postsynaptic density protein 95 in both VTA sub-regions, without altering the density of the astrocytic glutamatergic transporter GLT1. Finally, we identify several sub-populations of microglia in the VTA that differ between its anterior and posterior sub-parts, and show that they are re-organized in conditions of gut microbiota depletion. The present study paves the way for refining our understanding of the pathophysiology of nicotine addiction.

Identifiants

pubmed: 36932179
doi: 10.1038/s41386-023-01563-x
pii: 10.1038/s41386-023-01563-x
pmc: PMC10156728
doi:

Substances chimiques

Nicotine 6M3C89ZY6R
Dopamine VTD58H1Z2X

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

963-974

Informations de copyright

© 2023. The Author(s), under exclusive licence to American College of Neuropsychopharmacology.

Références

Neuropsychopharmacology. 2011 Apr;36(5):1021-32
pubmed: 21289604
CNS Neurol Disord Drug Targets. 2015;14(6):745-56
pubmed: 26022265
Cell. 2018 Sep 6;174(6):1406-1423.e16
pubmed: 30193113
Neuroimage. 2019 Oct 15;200:121-131
pubmed: 31201984
Neuropsychopharmacology. 2018 Dec;43(13):2606-2614
pubmed: 30258112
Nat Med. 2016 Jun;22(6):586-97
pubmed: 27158906
Psychopharmacology (Berl). 2012 Mar;220(1):1-14
pubmed: 21901321
BMC Microbiol. 2020 Nov 11;20(1):340
pubmed: 33176677
Brain Res. 2006 Aug 30;1107(1):13-23
pubmed: 16854387
Nutrients. 2020 Dec 19;12(12):
pubmed: 33352789
Cell. 2016 Jun 16;165(7):1762-1775
pubmed: 27315483
Nat Rev Immunol. 2016 May 27;16(6):341-52
pubmed: 27231050
J Neurosci. 2014 Apr 16;34(16):5649-57
pubmed: 24741055
Neuron. 2022 Sep 21;110(18):3018-3035.e7
pubmed: 35921846
Neuroscience. 2014 Dec 12;282:60-8
pubmed: 24875175
Proc Natl Acad Sci U S A. 2017 Dec 5;114(49):13012-13017
pubmed: 29158387
Chem Res Toxicol. 2017 Dec 18;30(12):2110-2119
pubmed: 29035044
Neurochem Int. 1998 Oct;33(4):287-97
pubmed: 9840219
J Neurosci. 2008 Nov 19;28(47):12318-27
pubmed: 19020025
J Neurosci. 2015 Jun 24;35(25):9409-23
pubmed: 26109664
Nicotine Tob Res. 2007 Mar;9(3):315-27
pubmed: 17365764
Neuropharmacology. 2009 Sep;57(4):347-55
pubmed: 19619563
Neuroscience. 2014 Dec 12;282:198-216
pubmed: 25241061
J Neurosci. 2021 Feb 24;41(8):1779-1787
pubmed: 33380469
J Neuroinflammation. 2016 Jun 17;13(1):153
pubmed: 27317566
Brain Pathol. 2020 Nov;30(6):1159-1177
pubmed: 33073887
Sci Adv. 2019 Oct 16;5(10):eaay9763
pubmed: 31663029
Eur J Neurosci. 2019 Sep;50(6):3014-3027
pubmed: 30968489
J Pharmacol Exp Ther. 2003 Nov;307(2):526-34
pubmed: 12970387
Eur J Neurosci. 2015 Nov;42(9):2633-43
pubmed: 26370007
J Neuroinflammation. 2012 Apr 24;9:74
pubmed: 22531301
Nat Neurosci. 2017 Feb;20(2):145-155
pubmed: 28092661
Eur J Neurosci. 2019 Aug;50(3):2574-2589
pubmed: 30240518
Proc Natl Acad Sci U S A. 2019 Dec 17;116(51):25968-25973
pubmed: 31776253
Sci Rep. 2018 Jan 19;8(1):1275
pubmed: 29352191
Science. 2004 Nov 5;306(5698):1029-32
pubmed: 15528443
CNS Drugs. 2014 Oct;28(10):875-86
pubmed: 24958205
J Neurochem. 2009 Jul;110(1):264-74
pubmed: 19457061
Addict Behav. 2010 Aug;35(8):771-8
pubmed: 20385446
Neuropharmacology. 2008 Jun;54(8):1223-32
pubmed: 18452957
J Neurochem. 2000 Sep;75(3):1076-84
pubmed: 10936189
Neurobiol Stress. 2017 Mar 19;7:124-136
pubmed: 29276734
Drug Alcohol Depend. 2017 Nov 1;180:156-170
pubmed: 28892721
Neuropsychopharmacology. 2016 Jun;41(7):1790-802
pubmed: 26585290
Ann N Y Acad Sci. 2015 Sep;1349:46-63
pubmed: 26301866
Nature. 2005 Jul 7;436(7047):103-7
pubmed: 16001069
Microorganisms. 2022 May 30;10(6):
pubmed: 35744645
Front Neurosci. 2017 Sep 15;11:490
pubmed: 28966571
J Neurochem. 2021 Jun;157(5):1495-1524
pubmed: 33368280
J Neurosci. 2018 Aug 1;38(31):6900-6920
pubmed: 29954848
Psychopharmacology (Berl). 2006 Aug;187(2):189-99
pubmed: 16752141
Cell. 2018 Jan 25;172(3):500-516.e16
pubmed: 29275859
Curr Opin Behav Sci. 2018 Oct;23:196-202
pubmed: 31341936
Eur J Neurosci. 2016 Dec;44(12):2975-2983
pubmed: 27711998
Nat Neurosci. 2015 Jul;18(7):965-77
pubmed: 26030851
Curr Biol. 2018 Oct 22;28(20):3244-3253.e7
pubmed: 30293722
Front Physiol. 2018 Oct 31;9:1534
pubmed: 30429801
Mol Neurobiol. 2009 Oct;40(2):139-56
pubmed: 19629762
Glia. 2005 Mar;49(4):520-41
pubmed: 15578656
PLoS One. 2014 Aug 29;9(8):e103740
pubmed: 25170769
Proc Natl Acad Sci U S A. 2007 May 8;104(19):8155-60
pubmed: 17470777
Neurosci Biobehav Rev. 2010 Mar;34(3):295-342
pubmed: 19665479
Brain Res Rev. 2007 Nov;56(1):27-78
pubmed: 17574681
Neuropharmacology. 2006 Jun;50(8):1030-40
pubmed: 16580026
Cell. 2018 Oct 18;175(3):887-888
pubmed: 30340046
Front Nutr. 2021 Nov 26;8:750333
pubmed: 34901109
Neuroscience. 2015 Dec 3;310:629-40
pubmed: 26440295
J Neuroinflammation. 2014 Jan 21;11:12
pubmed: 24447857
Gastroenterology. 2011 Aug;141(2):599-609, 609.e1-3
pubmed: 21683077
Mol Psychiatry. 2013 Mar;18(3):382-93
pubmed: 22751493
Psychopharmacology (Berl). 2010 Jul;211(1):43-54
pubmed: 20437028
Front Biosci. 2006 Sep 01;11:2400-19
pubmed: 16720322
Neuron. 2019 Jan 16;101(2):246-259.e6
pubmed: 30522820
Biol Psychiatry. 2017 Apr 1;81(7):625-634
pubmed: 27737762
Neuropharmacology. 2014 Jan;76 Pt B:329-41
pubmed: 23664810
J Transl Med. 2017 Jan 13;15(1):13
pubmed: 28086815
J Neurosci. 2020 Apr 22;40(17):3465-3477
pubmed: 32184221
Neuron. 2017 Jul 19;95(2):341-356.e6
pubmed: 28689984
Trends Cogn Sci. 2019 May;23(5):435-448
pubmed: 30948204
Curr Opin Pharmacol. 2007 Feb;7(1):69-76
pubmed: 17174602
J Neuroendocrinol. 2021 May;33(5):e12924
pubmed: 34019340
Psychopharmacology (Berl). 2013 Aug;228(3):419-26
pubmed: 23503685
Pharmacol Rev. 2022 Jan;74(1):271-310
pubmed: 35017179
Sci Rep. 2016 Oct 18;6:35455
pubmed: 27752130
J Neurosci. 2000 Aug 15;20(16):6309-16
pubmed: 10934283
Psychopharmacology (Berl). 2019 May;236(5):1513-1530
pubmed: 30982128
Curr Opin Neurobiol. 2019 Aug;57:179-185
pubmed: 31163290
Adv Pharmacol. 2014;69:1-69
pubmed: 24484974
Nat Rev Dis Primers. 2022 Mar 24;8(1):19
pubmed: 35332148
Exp Neurol. 2020 Mar;325:113159
pubmed: 31843492

Auteurs

Alina Lakosa (A)

Institut Pasteur, Université Paris Cité, Neurobiologie Intégrative des Systèmes Cholinergiques, CNRS UMR 3571, Paris, France.

Anaïs Rahimian (A)

Institut Pasteur, Université Paris Cité, Neurobiologie Intégrative des Systèmes Cholinergiques, CNRS UMR 3571, Paris, France.

Flavio Tomasi (F)

Institut Pasteur, Université Paris Cité, Neurobiologie Intégrative des Systèmes Cholinergiques, CNRS UMR 3571, Paris, France.
Neuroscience Paris Seine, Sorbonne Université, INSERM, CNRS, 75005 Paris, France.

Fabio Marti (F)

Plasticité du Cerveau, CNRS UMR 8249, ESPCI Paris, Université PSL, Paris, France.
Neuroscience Paris Seine, Sorbonne Université, INSERM, CNRS, 75005, Paris, France.

Lauren M Reynolds (LM)

Plasticité du Cerveau, CNRS UMR 8249, ESPCI Paris, Université PSL, Paris, France.

Léa Tochon (L)

Université de Bordeaux, Bordeaux, France.
CNRS UMR 5287, Institut de Neurosciences Cognitives et Intégratives d'Aquitaine, Bordeaux, France.

Vincent David (V)

Université de Bordeaux, Bordeaux, France.
CNRS UMR 5287, Institut de Neurosciences Cognitives et Intégratives d'Aquitaine, Bordeaux, France.

Anne Danckaert (A)

UTechS Photonics Bioimaging/C2RT, Institut Pasteur, Université Paris Cité, 25 rue du Dr Roux, 75724, Paris Cedex 15, France.

Candice Canonne (C)

Institut Pasteur, Université Paris Cité, Neurobiologie Intégrative des Systèmes Cholinergiques, CNRS UMR 3571, Paris, France.

Sylvana Tahraoui (S)

Institut Pasteur, Université Paris Cité, Neurobiologie Intégrative des Systèmes Cholinergiques, CNRS UMR 3571, Paris, France.

Fabrice de Chaumont (F)

Génétique humaine et fonctions cognitives, CNRS UMR 3571, Institut Pasteur, Université Paris Cité, 25 rue du Dr Roux, 75724, Paris Cedex 15, France.

Benoît Forget (B)

Institut Pasteur, Université Paris Cité, Neurobiologie Intégrative des Systèmes Cholinergiques, CNRS UMR 3571, Paris, France.
Génétique humaine et fonctions cognitives, CNRS UMR 3571, Institut Pasteur, Université Paris Cité, 25 rue du Dr Roux, 75724, Paris Cedex 15, France.

Uwe Maskos (U)

Institut Pasteur, Université Paris Cité, Neurobiologie Intégrative des Systèmes Cholinergiques, CNRS UMR 3571, Paris, France.

Morgane Besson (M)

Institut Pasteur, Université Paris Cité, Neurobiologie Intégrative des Systèmes Cholinergiques, CNRS UMR 3571, Paris, France. morgane.besson@pasteur.fr.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH